Clinical Trial Update: Lactobacillus Reuteri ATCC PTA 4659 in Ulcerative Colitis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for Lactobacillus reuteri ATCC PTA 4659 in Ulcerative Colitis flare.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Lactobacillus reuteri ATCC PTA 4659 (Lactobacillus reuteri ATCC PTA 4659)

Snippet

Sponsor: Uppsala University | Conditions: Ulcerative Colitis Flare | Phase 2 | Status: UNKNOWN